Back to top
more

Zevia (ZVIA)

(Delayed Data from NYSE)

$3.44 USD

3.44
1,200,007

+0.16 (4.88%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $3.70 +0.26 (7.56%) 7:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Beverages - Soft drinks

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Zevia (ZVIA) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Zevia (ZVIA) delivered earnings and revenue surprises of 63.64% and 5.60%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Neogen (NEOG) Misses Q1 Earnings Estimates

by Zacks Equity Research

Neogen (NEOG) delivered earnings and revenue surprises of -30% and 0.39%, respectively, for the quarter ended August 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zevia (ZVIA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Zevia (ZVIA) delivered earnings and revenue surprises of 30.77% and 2.13%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zevia (ZVIA) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Zevia (ZVIA) delivered earnings and revenue surprises of 0% and 2.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AtriCure (ATRC) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

AtriCure (ATRC) delivered earnings and revenue surprises of 4.55% and 0.04%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zynex Inc. (ZYXI) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 125% and 1.02%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

After Plunging -22.28% in 4 Weeks, Here's Why the Trend Might Reverse for Zevia (ZVIA)

by Zacks Equity Research

Zevia (ZVIA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

New Strong Buy Stocks for July 26th

by Zacks Equity Research

ANGI, SFIX, ZVIA, ZYME and HOWL have been added to the Zacks Rank #1 (Strong Buy) List on July 26, 2023.

Zacks Equity Research

What Makes Zevia (ZVIA) a New Strong Buy Stock

by Zacks Equity Research

Zevia (ZVIA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Best Momentum Stocks to Buy for July 13

by Zacks Equity Research

ACVA, MDB and ZVIA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 13, 2023.

Zacks Equity Research

Zevia (ZVIA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Zevia (ZVIA) delivered earnings and revenue surprises of 76.47% and 3.59%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

AtriCure (ATRC) delivered earnings and revenue surprises of 32.35% and 6.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zevia (ZVIA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Zevia (ZVIA) delivered earnings and revenue surprises of 16.67% and 15.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zevia (ZVIA) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Zevia (ZVIA) delivered earnings and revenue surprises of 19.05% and 7.43%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Canopy Growth Corporation (CGC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of -55.56% and 0.87%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Bio-Rad Laboratories (BIO) Surpasses Q3 Earnings Estimates

by Zacks Equity Research

Bio-Rad (BIO) delivered earnings and revenue surprises of 0.39% and 1.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zevia (ZVIA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Zevia (ZVIA) delivered earnings and revenue surprises of -55.56% and 7.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -755% and 3.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

TG Therapeutics (TGTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

TG Therapeutics (TGTX) delivered earnings and revenue surprises of 38.78% and 590.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?